Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Agendia Publishes Direct Evidence That MammaPrint Predicts Benefit of Chemotherapy in Breast Cancer
March 5th, 2009
Agendia, a world leader in molecular cancer diagnostics, announced that a study demonstrating the direct predictive ability of its breast cancer recurrence test, MammaPrint(R), has been published in Breast Cancer Research and Treatment. Additionally, the study authors have been invited to present the data at the American Association for Cancer Research's 2009 Annual Meeting in Denver, Colorado. "Our multi-study pool of patient data is maturing quickly and this is the first of a number of forthcoming publications showing MammaPrint's direct predictive ability for neoadjuvant and adjuvant chemotherapy regimens," commented Dr. Bernhard Sixt, Ph.D., President and Chief...
Source: Women's Health Weekly (2009-03-05)
|
